---
document_datetime: 2025-12-13 23:50:10
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/adynovi.html
document_name: adynovi.html
version: success
processing_time: 0.1212623
conversion_datetime: 2025-12-28 09:48:56.915453
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Adynovi

[RSS](/en/individual-human-medicine.xml/66137)

##### Authorised

This medicine is authorised for use in the European Union

rurioctocog alfa pegol Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Adynovi](#news-on)
- [More information on Adynovi](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Adynovi. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Adynovi.

For practical information about using Adynovi, patients should read the package leaflet or contact their doctor or pharmacist.

Expand section

Collapse section

## What is Adynovi and what is it used for?

Adynovi is a medicine used to treat and prevent bleeding in patients with haemophilia A, an inherited bleeding disorder caused by lack of a clotting protein called factor VIII. It can be used in adults and children from 12 years of age.

Adynovi contains the active substance rurioctocog alfa pegol.

## How is Adynovi used?

Adynovi can only be obtained with a prescription and treatment should be under the supervision of a doctor who has experience in the treatment of haemophilia.

Adynovi is available as a powder and solvent that are mixed together to make a solution for injection into a vein. The dose and frequency of treatment depend on whether it is used to treat or prevent bleeding, as well as on the seriousness of the haemophilia, the extent and location of the bleeding and the patient's condition and bodyweight. Patients or their carers may be able to inject Adynovi themselves at home once they have been trained appropriately.

For further details, see the package leaflet.

## How does Adynovi work?

Patients with haemophilia A lack factor VIII, a protein needed for normal clotting of the blood, and as a result, they bleed readily. The active substance in Adynovi, rurioctocog alfa pegol, works in the body in the same way as human factor VIII. It replaces the missing factor VIII, thereby helping the blood to clot and giving temporary control of the bleeding disorder.

## What benefits of Adynovi have been shown in studies?

Adynovi has been shown in two main studies to be effective at preventing and treating bleeding episodes in patients with severe haemophilia who were previously treated with other factor VIII products.

In a study involving 138 adults and adolescents aged 12 years or above, 120 patients given Adynovi as a twice-weekly preventive treatment had, on average, around 4 bleeding episodes a year, and 17 patients given Adynovi for treating bleedings 'on demand' had around 43 bleeding episodes a year. In addition, when bleeding did occur, Adynovi was rated excellent or good at treating around 96% of bleeding episodes. Around 96% of bleeding episodes resolved with one or two injections of Adynovi.

In the second study in 66 children aged below 12 years, all patients were given Adynovi as a twice-weekly preventive treatment for around 6 months. During this period, around 38% of patients (25 out of 66) had no bleeding episodes, and none of the patients developed antibodies against Adynovi, which can cause the medicine to stop working. When bleeding occurred, Adynovi was rated excellent or good at treating around 90% of episodes. Around 83% of bleeding episodes resolved with one injection.

## What are the risks associated with Adynovi?

Hypersensitivity (allergic) reactions are uncommon with Adynovi (affecting up to 1 in 100 people) and may include swelling, burning and stinging at the injection site, chills, flushing, itchy rash, headache, hives, low blood pressure, lethargy, nausea and vomiting, restlessness, a rapid heartbeat, tightness of the chest and wheezing. In some cases these reactions can become severe.

Following treatment with factor VIII products, including Adynovi, some patients may develop inhibitors (antibodies) against factor VIII, causing the medicine to stop working and resulting in a loss of bleeding control. In such cases, a specialised haemophilia centre should be contacted.

For the full list of all side effects see the package leaflet.

Adynovi must not be used in patients who are hypersensitive (allergic) to rurioctocog alfa pegol or the related substance octocog alfa or to any of the other ingredients of the medicine, nor in those with known allergy to mouse or hamster proteins.

## Why is Adynovi approved?

The European Medicines Agency decided that Adynovi's benefits are greater than its risks and recommended that it be approved for use in the EU. Studies show that Adynovi is effective at preventing and treating bleeding episodes in patients with haemophilia A and its safety is comparable to that of other factor VIII products. However, part of the active substance in Adynovi (called PEG) may accumulate in the body, including in a structure in the brain called the choroid plexus, following long-term treatment. Since this could potentially cause problems especially in children below 12 years of age, Adynovi is only approved for use in adults and children from 12 years of age.

## What measures are being taken to ensure the safe and effective use of Adynovi?

The company that markets Adynovi will conduct a study to investigate the potential effects of PEG accumulation in the choroid plexus of the brain and other organs.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Adynovi have also been included in the summary of product characteristics and the package leaflet.

## Other information about Adynovi

The European Commission granted a marketing authorisation valid throughout the European Union for Adynovi on 8 January 2018.

For more information about treatment with Adynovi, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Adynovi : EPAR - Summary for the public

English (EN) (77.15 KB - PDF)

**First published:** 16/02/2018

**Last updated:** 16/02/2018

[View](/en/documents/overview/adynovi-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-964)

български (BG) (104.2 KB - PDF)

**First published:**

16/02/2018

**Last updated:**

16/02/2018

[View](/bg/documents/overview/adynovi-epar-summary-public_bg.pdf)

español (ES) (76.09 KB - PDF)

**First published:**

16/02/2018

**Last updated:**

16/02/2018

[View](/es/documents/overview/adynovi-epar-summary-public_es.pdf)

čeština (CS) (102.37 KB - PDF)

**First published:**

16/02/2018

**Last updated:**

16/02/2018

[View](/cs/documents/overview/adynovi-epar-summary-public_cs.pdf)

dansk (DA) (75.22 KB - PDF)

**First published:**

16/02/2018

**Last updated:**

16/02/2018

[View](/da/documents/overview/adynovi-epar-summary-public_da.pdf)

Deutsch (DE) (77.36 KB - PDF)

**First published:**

16/02/2018

**Last updated:**

16/02/2018

[View](/de/documents/overview/adynovi-epar-summary-public_de.pdf)

eesti keel (ET) (74.99 KB - PDF)

**First published:**

16/02/2018

**Last updated:**

16/02/2018

[View](/et/documents/overview/adynovi-epar-summary-public_et.pdf)

ελληνικά (EL) (105.53 KB - PDF)

**First published:**

16/02/2018

**Last updated:**

16/02/2018

[View](/el/documents/overview/adynovi-epar-summary-public_el.pdf)

français (FR) (76.9 KB - PDF)

**First published:**

16/02/2018

**Last updated:**

16/02/2018

[View](/fr/documents/overview/adynovi-epar-summary-public_fr.pdf)

hrvatski (HR) (97.37 KB - PDF)

**First published:**

16/02/2018

**Last updated:**

16/02/2018

[View](/hr/documents/overview/adynovi-epar-summary-public_hr.pdf)

italiano (IT) (75.15 KB - PDF)

**First published:**

16/02/2018

**Last updated:**

16/02/2018

[View](/it/documents/overview/adynovi-epar-summary-public_it.pdf)

latviešu valoda (LV) (99.02 KB - PDF)

**First published:**

16/02/2018

**Last updated:**

16/02/2018

[View](/lv/documents/overview/adynovi-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (100 KB - PDF)

**First published:**

16/02/2018

**Last updated:**

16/02/2018

[View](/lt/documents/overview/adynovi-epar-summary-public_lt.pdf)

magyar (HU) (97.02 KB - PDF)

**First published:**

16/02/2018

**Last updated:**

16/02/2018

[View](/hu/documents/overview/adynovi-epar-summary-public_hu.pdf)

Malti (MT) (101.95 KB - PDF)

**First published:**

16/02/2018

**Last updated:**

16/02/2018

[View](/mt/documents/overview/adynovi-epar-summary-public_mt.pdf)

Nederlands (NL) (75.7 KB - PDF)

**First published:**

16/02/2018

**Last updated:**

16/02/2018

[View](/nl/documents/overview/adynovi-epar-summary-public_nl.pdf)

polski (PL) (102.3 KB - PDF)

**First published:**

16/02/2018

**Last updated:**

16/02/2018

[View](/pl/documents/overview/adynovi-epar-summary-public_pl.pdf)

português (PT) (76.24 KB - PDF)

**First published:**

16/02/2018

**Last updated:**

16/02/2018

[View](/pt/documents/overview/adynovi-epar-summary-public_pt.pdf)

română (RO) (98.75 KB - PDF)

**First published:**

16/02/2018

**Last updated:**

16/02/2018

[View](/ro/documents/overview/adynovi-epar-summary-public_ro.pdf)

slovenčina (SK) (101.1 KB - PDF)

**First published:**

16/02/2018

**Last updated:**

16/02/2018

[View](/sk/documents/overview/adynovi-epar-summary-public_sk.pdf)

slovenščina (SL) (95.36 KB - PDF)

**First published:**

16/02/2018

**Last updated:**

16/02/2018

[View](/sl/documents/overview/adynovi-epar-summary-public_sl.pdf)

Suomi (FI) (74.71 KB - PDF)

**First published:**

16/02/2018

**Last updated:**

16/02/2018

[View](/fi/documents/overview/adynovi-epar-summary-public_fi.pdf)

svenska (SV) (75.53 KB - PDF)

**First published:**

16/02/2018

**Last updated:**

16/02/2018

[View](/sv/documents/overview/adynovi-epar-summary-public_sv.pdf)

Adynovi : EPAR - Risk management plan summary

English (EN) (277.64 KB - PDF)

**First published:** 04/02/2022

**Last updated:** 02/06/2023

[View](/en/documents/rmp-summary/adynovi-epar-risk-management-plan-summary_en.pdf)

## Product information

Adynovi : EPAR - Product Information

English (EN) (1.51 MB - PDF)

**First published:** 16/02/2018

**Last updated:** 03/10/2023

[View](/en/documents/product-information/adynovi-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-106)

български (BG) (2.28 MB - PDF)

**First published:**

16/02/2018

**Last updated:**

03/10/2023

[View](/bg/documents/product-information/adynovi-epar-product-information_bg.pdf)

español (ES) (1.46 MB - PDF)

**First published:**

16/02/2018

**Last updated:**

03/10/2023

[View](/es/documents/product-information/adynovi-epar-product-information_es.pdf)

čeština (CS) (2.14 MB - PDF)

**First published:**

16/02/2018

**Last updated:**

03/10/2023

[View](/cs/documents/product-information/adynovi-epar-product-information_cs.pdf)

dansk (DA) (1.37 MB - PDF)

**First published:**

16/02/2018

**Last updated:**

03/10/2023

[View](/da/documents/product-information/adynovi-epar-product-information_da.pdf)

Deutsch (DE) (1.45 MB - PDF)

**First published:**

16/02/2018

**Last updated:**

03/10/2023

[View](/de/documents/product-information/adynovi-epar-product-information_de.pdf)

eesti keel (ET) (1.48 MB - PDF)

**First published:**

16/02/2018

**Last updated:**

03/10/2023

[View](/et/documents/product-information/adynovi-epar-product-information_et.pdf)

ελληνικά (EL) (2.35 MB - PDF)

**First published:**

16/02/2018

**Last updated:**

03/10/2023

[View](/el/documents/product-information/adynovi-epar-product-information_el.pdf)

français (FR) (1.51 MB - PDF)

**First published:**

16/02/2018

**Last updated:**

03/10/2023

[View](/fr/documents/product-information/adynovi-epar-product-information_fr.pdf)

hrvatski (HR) (1.96 MB - PDF)

**First published:**

16/02/2018

**Last updated:**

03/10/2023

[View](/hr/documents/product-information/adynovi-epar-product-information_hr.pdf)

íslenska (IS) (1.37 MB - PDF)

**First published:**

16/02/2018

**Last updated:**

03/10/2023

[View](/is/documents/product-information/adynovi-epar-product-information_is.pdf)

italiano (IT) (1.46 MB - PDF)

**First published:**

16/02/2018

**Last updated:**

03/10/2023

[View](/it/documents/product-information/adynovi-epar-product-information_it.pdf)

latviešu valoda (LV) (2.19 MB - PDF)

**First published:**

16/02/2018

**Last updated:**

03/10/2023

[View](/lv/documents/product-information/adynovi-epar-product-information_lv.pdf)

lietuvių kalba (LT) (2.08 MB - PDF)

**First published:**

16/02/2018

**Last updated:**

03/10/2023

[View](/lt/documents/product-information/adynovi-epar-product-information_lt.pdf)

magyar (HU) (1.89 MB - PDF)

**First published:**

16/02/2018

**Last updated:**

03/10/2023

[View](/hu/documents/product-information/adynovi-epar-product-information_hu.pdf)

Malti (MT) (2.37 MB - PDF)

**First published:**

16/02/2018

**Last updated:**

03/10/2023

[View](/mt/documents/product-information/adynovi-epar-product-information_mt.pdf)

Nederlands (NL) (1.53 MB - PDF)

**First published:**

16/02/2018

**Last updated:**

03/10/2023

[View](/nl/documents/product-information/adynovi-epar-product-information_nl.pdf)

norsk (NO) (1.48 MB - PDF)

**First published:**

16/02/2018

**Last updated:**

03/10/2023

[View](/no/documents/product-information/adynovi-epar-product-information_no.pdf)

polski (PL) (2.17 MB - PDF)

**First published:**

16/02/2018

**Last updated:**

03/10/2023

[View](/pl/documents/product-information/adynovi-epar-product-information_pl.pdf)

português (PT) (1.49 MB - PDF)

**First published:**

16/02/2018

**Last updated:**

03/10/2023

[View](/pt/documents/product-information/adynovi-epar-product-information_pt.pdf)

română (RO) (2.21 MB - PDF)

**First published:**

16/02/2018

**Last updated:**

03/10/2023

[View](/ro/documents/product-information/adynovi-epar-product-information_ro.pdf)

slovenčina (SK) (3.97 MB - PDF)

**First published:**

16/02/2018

**Last updated:**

03/10/2023

[View](/sk/documents/product-information/adynovi-epar-product-information_sk.pdf)

slovenščina (SL) (3.43 MB - PDF)

**First published:**

16/02/2018

**Last updated:**

03/10/2023

[View](/sl/documents/product-information/adynovi-epar-product-information_sl.pdf)

Suomi (FI) (1.44 MB - PDF)

**First published:**

16/02/2018

**Last updated:**

03/10/2023

[View](/fi/documents/product-information/adynovi-epar-product-information_fi.pdf)

svenska (SV) (1.37 MB - PDF)

**First published:**

16/02/2018

**Last updated:**

03/10/2023

[View](/sv/documents/product-information/adynovi-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** II/0035 13/07/2023

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Adynovi : EPAR - All Authorised presentations

English (EN) (61.83 KB - PDF)

**First published:** 16/02/2018

**Last updated:** 04/02/2022

[View](/en/documents/all-authorised-presentations/adynovi-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-205)

български (BG) (63.82 KB - PDF)

**First published:**

16/02/2018

**Last updated:**

04/02/2022

[View](/bg/documents/all-authorised-presentations/adynovi-epar-all-authorised-presentations_bg.pdf)

español (ES) (59.26 KB - PDF)

**First published:**

16/02/2018

**Last updated:**

04/02/2022

[View](/es/documents/all-authorised-presentations/adynovi-epar-all-authorised-presentations_es.pdf)

čeština (CS) (64.99 KB - PDF)

**First published:**

16/02/2018

**Last updated:**

04/02/2022

[View](/cs/documents/all-authorised-presentations/adynovi-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (64.66 KB - PDF)

**First published:**

16/02/2018

**Last updated:**

04/02/2022

[View](/da/documents/all-authorised-presentations/adynovi-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (67.66 KB - PDF)

**First published:**

16/02/2018

**Last updated:**

04/02/2022

[View](/de/documents/all-authorised-presentations/adynovi-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (61.35 KB - PDF)

**First published:**

16/02/2018

**Last updated:**

04/02/2022

[View](/et/documents/all-authorised-presentations/adynovi-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (55.09 KB - PDF)

**First published:**

16/02/2018

**Last updated:**

04/02/2022

[View](/el/documents/all-authorised-presentations/adynovi-epar-all-authorised-presentations_el.pdf)

français (FR) (60.78 KB - PDF)

**First published:**

16/02/2018

**Last updated:**

04/02/2022

[View](/fr/documents/all-authorised-presentations/adynovi-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (60.21 KB - PDF)

**First published:**

16/02/2018

**Last updated:**

04/02/2022

[View](/hr/documents/all-authorised-presentations/adynovi-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (62.1 KB - PDF)

**First published:**

16/02/2018

**Last updated:**

04/02/2022

[View](/is/documents/all-authorised-presentations/adynovi-epar-all-authorised-presentations_is.pdf)

italiano (IT) (59.31 KB - PDF)

**First published:**

16/02/2018

**Last updated:**

04/02/2022

[View](/it/documents/all-authorised-presentations/adynovi-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (62.53 KB - PDF)

**First published:**

16/02/2018

**Last updated:**

04/02/2022

[View](/lv/documents/all-authorised-presentations/adynovi-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (63.16 KB - PDF)

**First published:**

16/02/2018

**Last updated:**

04/02/2022

[View](/lt/documents/all-authorised-presentations/adynovi-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (62.89 KB - PDF)

**First published:**

16/02/2018

**Last updated:**

04/02/2022

[View](/hu/documents/all-authorised-presentations/adynovi-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (65.78 KB - PDF)

**First published:**

16/02/2018

**Last updated:**

04/02/2022

[View](/mt/documents/all-authorised-presentations/adynovi-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (61.96 KB - PDF)

**First published:**

16/02/2018

**Last updated:**

04/02/2022

[View](/nl/documents/all-authorised-presentations/adynovi-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (64.28 KB - PDF)

**First published:**

16/02/2018

**Last updated:**

04/02/2022

[View](/no/documents/all-authorised-presentations/adynovi-epar-all-authorised-presentations_no.pdf)

polski (PL) (65.87 KB - PDF)

**First published:**

16/02/2018

**Last updated:**

04/02/2022

[View](/pl/documents/all-authorised-presentations/adynovi-epar-all-authorised-presentations_pl.pdf)

português (PT) (62.35 KB - PDF)

**First published:**

16/02/2018

**Last updated:**

04/02/2022

[View](/pt/documents/all-authorised-presentations/adynovi-epar-all-authorised-presentations_pt.pdf)

română (RO) (60.22 KB - PDF)

**First published:**

16/02/2018

**Last updated:**

04/02/2022

[View](/ro/documents/all-authorised-presentations/adynovi-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (65.14 KB - PDF)

**First published:**

16/02/2018

**Last updated:**

04/02/2022

[View](/sk/documents/all-authorised-presentations/adynovi-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (59.98 KB - PDF)

**First published:**

16/02/2018

**Last updated:**

04/02/2022

[View](/sl/documents/all-authorised-presentations/adynovi-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (58.32 KB - PDF)

**First published:**

16/02/2018

**Last updated:**

04/02/2022

[View](/fi/documents/all-authorised-presentations/adynovi-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (60.65 KB - PDF)

**First published:**

16/02/2018

**Last updated:**

04/02/2022

[View](/sv/documents/all-authorised-presentations/adynovi-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Adynovi Active substance rurioctocog alfa pegol International non-proprietary name (INN) or common name rurioctocog alfa pegol Therapeutic area (MeSH) Hemophilia A Anatomical therapeutic chemical (ATC) code B02BD02

### Pharmacotherapeutic group

Antihemorrhagics

### Therapeutic indication

Treatment and prophylaxis of bleeding in patients 12 years and above with haemophilia A (congenital factor VIII deficiency).

## Authorisation details

EMA product number EMEA/H/C/004195

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Marketing authorisation holder

Baxalta Innovations GmbH

Industriestrasse 67

Marketing authorisation issued 08/01/2018 Revision 15

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Adynovi : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (203.41 KB - PDF)

**First published:** 09/04/2018

**Last updated:** 05/12/2025

[View](/en/documents/procedural-steps-after/adynovi-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Adynovi-PAM-0000258131 : EPAR - Assessment report

Adopted

Reference Number: EMADOC-1700519818-2470961

English (EN) (1.36 MB - PDF)

**First published:** 01/12/2025

[View](/en/documents/variation-report/adynovi-pam-0000258131-epar-assessment-report_en.pdf)

Adynovi-PAM-0000245372 : EPAR - Assessment report

Adopted

Reference Number: EMADOC-1700519818-2272682

English (EN) (715.73 KB - PDF)

**First published:** 01/12/2025

[View](/en/documents/variation-report/adynovi-pam-0000245372-epar-assessment-report_en.pdf)

Adynovi-H-C-004195-P46-018 : EPAR - Assessment report

Adopted

Reference Number: EMA/3053/2025

English (EN) (345.47 KB - PDF)

**First published:** 15/01/2025

[View](/en/documents/variation-report/adynovi-h-c-004195-p46-018-epar-assessment-report_en.pdf)

Adynovi-H-C-004195-P46-016 : EPAR - Assessment report

Adopted

Reference Number: EMA/596204/2024

English (EN) (1.48 MB - PDF)

**First published:** 06/01/2025

[View](/en/documents/variation-report/adynovi-h-c-004195-p46-016-epar-assessment-report_en.pdf)

Adynovi-H-C-004195-P46-015 : EPAR - Assessment report

Adopted

Reference Number: EMA/CHMP/260738/2024

English (EN) (13.38 MB - PDF)

**First published:** 08/11/2024

[View](/en/documents/variation-report/adynovi-h-c-004195-p46-015-epar-assessment-report_en.pdf)

Adynovi-H-C-004195-P46-011 : EPAR - Assessment report

Adopted

Reference Number: EMA/148610/2024

English (EN) (1.99 MB - PDF)

**First published:** 19/06/2024

[View](/en/documents/variation-report/adynovi-h-c-004195-p46-011-epar-assessment-report_en.pdf-0)

Adynovi-H-C-004195-P46-011 : EPAR - Assessment report

Adopted

Reference Number: EMA/148610/2024

English (EN) (1.99 MB - PDF)

**First published:** 06/05/2024

[View](/en/documents/variation-report/adynovi-h-c-004195-p46-011-epar-assessment-report_en.pdf)

Adynovi-H-C-4195-P46-008.1 : EPAR - Assessment report

Adopted

Reference Number: EMA/467702/2019

English (EN) (887.06 KB - PDF)

**First published:** 23/08/2019

[View](/en/documents/variation-report/adynovi-h-c-4195-p46-0081-epar-assessment-report_en.pdf)

## Initial marketing authorisation documents

Adynovi : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/782768/2017

English (EN) (3.31 MB - PDF)

**First published:** 16/02/2018

**Last updated:** 16/02/2018

[View](/en/documents/assessment-report/adynovi-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Adynovi

Adopted

Reference Number: EMA/CHMP/708455/2017

English (EN) (68.06 KB - PDF)

**First published:** 10/11/2017

**Last updated:** 10/11/2017

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-adynovi_en.pdf)

#### News on Adynovi

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 6-9 November 2017](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-6-9-november-2017) 10/11/2017

#### More information on Adynovi

- [EMEA-001296-PIP01-12-M04 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001296-pip01-12-m04)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 05/12/2025

## Share this page

[Back to top](#main-content)